151521-49-2

Basic information

• Product Name: 4-Isopropyl-1H-pyrazol-3-amine
• Synonyms: 4-(1-Methylethyl)-1H-pyrazol-3-amine;4-Isopropyl-1H-pyrazol-3-amine;4-propan-2-yl-1H-pyrazol-5-amine;1H-Pyrazol-3-amine,4-(1-methylethyl)-(9CI);1H-Pyrazol-3-amine, 4-(1-methylethyl)-;4-ISO-PROPYL-1H-PYRAZOL-5-AMINE
• CAS NO: 151521-49-2
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17
• Product Categories: AMINEPRIMARY;PYRAZOLE
• Mol File: 151521-49-2.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 295.776 °C at 760 mmHg
• Flash Point: 157.794 °C
• Appearance: /
• Density: 1.104
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 16.12±0.50(Predicted)
• CAS DataBase Reference: 4-Isopropyl-1H-pyrazol-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Isopropyl-1H-pyrazol-3-amine(151521-49-2)
• EPA Substance Registry System: 4-Isopropyl-1H-pyrazol-3-amine(151521-49-2)

Safety Data

• Hazardous Substances Data: 151521-49-2(Hazardous Substances Data)

Usage

General Description

4-Isopropyl-1H-pyrazol-3-amine is a synthetic chemical compound that falls under the category of organic compounds known as pyrazolines. Pyrazolines are compounds containing a pyrazolines ring, which is a five-membered aromatic ring with two nitrogen atoms and one double bond. 4-Isopropyl-1H-pyrazol-3-amine is an isopropyl compound, which means it contains a substituent derived from propane that has one of its hydrogen atoms replaced by another group. The molecular formula of 4-Isopropyl-1H-pyrazol-3-amine is C7H13N3. Its exact mass and monoisotopic mass are 141.1106 g/mol and 141.1101 g/mol respectively. This chemical is not well-studied and may offer opportunities for future research.

InChI:InChI=1/C6H11N3/c1-4(2)5-3-8-9-6(5)7/h3-4H,1-2H3,(H3,7,8,9)

Upstream product

• 625-28-5 Isovaleronitrile 
• 107-31-3 Methyl formate 
• 771510-15-7 2-formyl-3-methylbutanenitrile 

Downstream Products

• 771510-32-8 5,7-dichloro-3-iso-propyl-pyrazolo[1,5-a]pyrimidine 
• 1092443-98-5 benzyl-(5-chloro-3-iso-propylpyrazolo[1,5-a]pyrimidin-7-yl)-amine 
• 1092444-33-1 benzyl (5-chloro-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamic acid tert-butyl ester 
• 1256288-44-4 tert-butyl benzyl(5-((6-((tert-butoxycarbonyl)amino)hexyl)amino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate 
• 1092444-48-8 tert-butyl (R)-benzyl-{5-[1-(tert-butyl-dimethylsilyloxy)-9-(6-fluoropyridin-3-yl)-non-2-ylamino]-3-isopropyl-pyrazolo[1,5-a]pyrimidin-7-yl}carbamate 
• 1092444-38-6 [(R)-6-{7-[tert-butoxycarbonyl-(2-fluoro-benzyl)-amino]-3-isopropyl-pyrazolo[1,5-a]pyrimidin-5-ylamino}-7-(tert-butyl-dimethyl-silanyloxy)-heptyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

CDK KINASE INHIBITOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION

Disclosed in the present invention are a CDK kinase inhibitor, a preparation method therefor, a pharmaceutical composition, and an application. The present invention provides a compound as represented by formula I-a, a cis-trans isomer thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof, a tautomer thereof, or a polymorph thereof. The compound of the present invention has good CDK7 inhibitory activity, cell activity, and tumor growth inhibitory activity.

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof

The invention relates to 2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof. Specifically, the invention discloses the compounds represented by a formula (I) shown in the specification, enantiomers, diastereomers, racemates or a mixture of the compounds, or a pharmaceutically acceptable salt, hydrate and solvate of the compounds, a preparation method of the above materials, and applications of the above materials in preparation of an ASK1 small molecule inhibitor, or medicines for preventing and/or treating diseases related to ASK1, especially liver diseases, lung diseases, cardiovascular diseases, kidney diseases and metabolic diseases.